Hereditary *BRCA1/2* pathogenic variants are present in 10%--20% of women with (nonborderline) epithelial ovarian, fallopian tube, and primary peritoneal cancer tumors (denoted as ovarian cancer \[OC\]). Early identification of pathogenic *BRCA1/2* variants can reduce morbidity and mortality from breast cancer and OC by preventive and curative strategies in both patients and families ([@djz080-B1],[@djz080-B2]). Generally, national guidelines therefore advise *BRCA1/2* genetic predisposition testing for all OC patients ([@djz080-B3],[@djz080-B4]). OC patients with pathogenic *BRCA1/2* variants in their tumor are likely to benefit from poly (ADP-ribose) polymerase inhibitor (PARPi) therapy ([@djz080-B5]). PARPi therapy improves prognosis in patients with platinum-sensitive OC and is most effective in OC with defective homologous recombination mediated repair, especially *BRCA1/2* defects ([@djz080-B9]). An estimated 18%--24% of patients with OC carry a *BRCA1/2* pathogenic variant in their tumor, often in the context of an inherited germline *BRCA1/2* variant. It is estimated that of the patients with a tumor *BRCA1/2* variant, 54%--74% represent hereditary defects and 27%--46% somatic defects that are present in the tumor only ([@djz080-B5]).

Because a tumor *BRCA1/2* test detects both hereditary and somatic *BRCA1/2* variants, we developed a new workflow starting with universal tumor DNA *BRCA1/2* testing in newly diagnosed OC patients. This workflow is based on our technical approach using single-molecule molecular inversion probe (smMIP) enrichment followed by next-generation sequencing (NGS) and allows rapid and reliable detection of both hereditary and somatic aberrations affecting *BRCA1/2* in DNA derived from formalin-fixed paraffin-embedded (FFPE) tissue of OC ([@djz080-B15]).

The new universal tumor *BRCA1/2* workflow has three key features. First, it detects many more patients who are eligible for PARPi therapy than conventional genetic predisposition testing of DNA from blood. Individuals can subsequently decide whether to continue with testing for a heritable *BRCA1/2* variant. Second, testing tumor DNA effectively serves as a prescreen to tailor genetic counseling to those with a high a priori risk of a hereditary pathogenic variant. Third, by focusing on treatment options, the strategy may improve uptake of *BRCA1/2* genetic predisposition in patients with OC.

In this study, the novel workflow of universal tumor DNA *BRCA1/2* testing was implemented in seven hospitals. Its feasibility, effectiveness, and appreciation were evaluated by uptake, diagnostic yield, and referral rates for subsequent genetic counseling. The experiences of patients and gynecologists were systematically assessed.

Methods
=======

Study Population
----------------

In this multicenter, observational cohort study, seven hospitals (two university and five regional) implemented universal tumor DNA *BRCA1/2* testing in standard care between October 2015 and June 2017. Universal tumor *BRCA1/2* testing was performed on tumor DNA from OC obtained by a diagnostic biopsy or a primary staging or cytoreductive surgery for OC. In a few cases, cells obtained from ascites aspiration were analyzed.

To measure uptake, OC patients (excluding borderline) were identified through a search of the nationwide registry of histo- and cytopathology (PALGA) ([@djz080-B16]). For all patients, referral for genetic counseling and genetic predisposition testing to the two genetic centers in the region and vital status were checked manually up to August 2018 ([Supplementary Figure 1](#sup1){ref-type="supplementary-material"}, available online). This study was approved by the privacy committee and the scientific board of PALGA and the medical ethical committee (NL 52165.091.15, 2015--1579). As required, written informed consent was obtained from the patients participating in the interviews. As part of diagnostics, patients provided oral informed consent for genetic testing.

Procedures
----------

Pathologists were instructed to submit FFPE OC samples for centralized tumor DNA *BRCA1/2* testing at the Radboud University Medical Center. Quality and quantity of tumor DNA (≥20% neoplastic cells) were evaluated centrally. Tumor DNA testing was performed with smMIP-based NGS of *BRCA1/2*, multiplex ligation-dependent probe amplification (MLPA), and methylation-specific MLPA of *BRCA1* ([@djz080-B15]). Pathogenic and likely pathogenic variants (subsequently pathogenic variants) in *BRCA1/2* were reported to the pathologist and gynecologist.

Gynecologists discussed the tumor DNA *BRCA1/2* test and its results with the patient and were instructed to refer consenting patients with a tumor *BRCA1/2* variant for genetic counseling if desired. Information for professionals and short videos for patients considering the difference between DNA testing in blood and in tumor tissue were provided after a positive tumor DNA *BRCA1/2* test result and before genetic testing (see www.cancergenetics.eu).

Outcomes
--------

The feasibility and effectiveness of the universal tumor *BRCA1/2* workflow was assessed by its diagnostic yield, uptake of tumor DNA *BRCA1/2* testing by pathologists, rate of successful testing, turnaround times, and referral rates for genetic counseling.

The appreciation of patients was assessed with semi-structured telephone interviews in a random sample of patients with somatic variants, germline variants, or without any variant. The appreciation of gynecologists in participating hospitals was assessed by a questionnaire.

Statistical Analysis
--------------------

Patient groups were compared using Mann-Whitney *U* tests and Fisher exact tests. Bonferroni correction was applied when assessing differences between three patient groups. *P* values less than .05 (two-tailed) were considered statistically significant. Analyses were performed with R software ([@djz080-B17]).

Results
=======

Uptake and Yield of Tumor DNA BRCA1/2 Testing
---------------------------------------------

A *BRCA1/2* tumor test was requested for 315 of 406 patients (77.6%) with newly diagnosed OC at a median age of 66 years (interquartile range \[IQR\] = 57--73; [Table 1](#djz080-T1){ref-type="table"}). Of the 91 patients without a tumor test, 20 patients (22.0%) were directly referred for genetic counseling and genetic predisposition testing ([Figure 1](#djz080-F1){ref-type="fig"}). During the active implementation of universal tumor testing, uptake increased from 58.8% in the first 4 months of implementation to 79.7% in the last 4 months ([Figure 2](#djz080-F2){ref-type="fig"}). The median time for tumor test request was 14 days (IQR = 8--21 days). Tumor *BRCA1/2* smMIP-based NGS testing was successful for 305 of 315 patients (97%). MLPA was not possible in eight (3.1%) of 254 patients with a negative smMIP-based NGS test result.
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###### 

Process evaluation of universal tumor *BRCA1/2* testing in epithelial ovarian cancer patients

  Workflow characteristics                                                                  Total OC cohort n = 406   *BRCA1/2* tumor testing n = 315
  ----------------------------------------------------------------------------------------- ------------------------- ---------------------------------
  Age at OC diagnosis, median (IQR), y                                                      66 (57--73)               66 (57--73)
  Histology, No. (%)                                                                                                  
   Serous, low grade                                                                        28 (6.9)                  18 (5.7)
   Serous, high grade                                                                       246 (60.6)                199 (63.2)
   Serous, unknown grade                                                                    19 (4.7)                  19 (6.0)
   Mucinous                                                                                 30 (7.4)                  17 (5.4)
   Endometrioid                                                                             23 (5.7)                  16 (5.1)
   Clear cell                                                                               25 (6.2)                  20 (6.3)
   Carcinosarcoma                                                                           13 (3.2)                  10 (3.2)
   Adenocarcinoma NOS                                                                       9 (2.2)                   3 (1.0)
   Undifferentiated                                                                         10 (2.5)                  10 (3.2)
   Other                                                                                    3 (0.7)                   3 (1.0)
  Uptake of tumor *BRCA1/2* testing by pathologists, No. (%)                                                          
   Overall uptake                                                                           315 (78)                  315 (100)
   Uptake within 3 months after OC diagnosis                                                290 (71)                  290 (92)
  Days from histological diagnosis to tumor BRCA1/2 test request, median (IQR)              --                        14 (8--2)
  Outcome of BRCA1/2 tumor test, No. (%)                                                                              
   Successful test                                                                          --                        305 (96.8)
   No test result available                                                                 --                        10 (3.2)
    Insufficient quality of DNA material                                                    --                        3 (1.0)
    Low tumor cell percentage                                                               --                        2 (0.6)
    Lack of material                                                                        --                        4 (1.3)
    Test retracted                                                                          --                        1 (0.3)
  BRCA1/2 tumor tests needed, No. (%)                                                                                 
   Successful after first test                                                              --                        292 (95.7)
   Successful after second test on different sample                                         --                        13 (4.3)
  Tissue used for tumor *BRCA1/2* test, No. (%)                                                                       
   Biopsy                                                                                   --                        64 (20.3)
   Ovariectomy, staging surgery, or debulking                                               --                        247 (78.4)
   Ascites                                                                                  --                        1 (0.3)
   Other                                                                                    --                        3 (1.0)
  Tumor *BRCA1/2* test on first histological sample, No. (%)                                                          
   Yes                                                                                      --                        209 (66.3)
   No                                                                                       --                        106 (33.7)
  Chemotherapy before resection of tissue used for testing, No. (%)                                                   
   Yes                                                                                      --                        105 (33.3)
   No                                                                                       --                        209 (66.3)
   Unknown                                                                                  --                        1 (0.3)
  *BRCA1/2* tumor (likely) pathogenic variants, No. (%)                                                               
   *BRCA1*                                                                                  --                        27 (8.9)
   *BRCA2*                                                                                  --                        24 (7.9)
   No (likely) pathogenic variant                                                           --                        254 (83.3)
  Days from *BRCA1/2* tumor test request to test result, median (IQR)                                                 14 (12--16)
  Referral rates by indication status, No. (%)                                                                        
   Positive tumor *BRCA1/2* test (n = 51)                                                   --                        45 (88.2)
   Unsuccessful tumor *BRCA1/2* test (n =10)                                                --                        8 (80.0)
   Negative tumor *BRCA1/2* test (n = 254)                                                  --                        34 (13.4)
    ≥1 OC FDR of those referred (n = 34)                                                    --                        2 (5.9)
   No tumor *BRCA1/2* test (n = 91)                                                         --                        20 (22.0)
  Appropriate referral rates                                                                                          
   Referral of those with referral indication[\*](#tblfn1){ref-type="table-fn"} (n = 63)    --                        55 (87.3)
   No referral of those without referral indication (n = 252)                               --                        220 (87.3)
  Days from histological diagnosis to referral of those with positive tumor test (n = 45)   --                        68 (46--161)
  Days from tumor *BRCA1/2* test result to referral, median (IQR)                                                     
   Referral time after any test result                                                      --                        39 (19--126)
   Referral time after test result indication to referral                                   --                        34 (22--102)

Indication for referral for cancer predisposition testing is: a positive or unsuccessful test or a negative tumor test but a first-degree family history of OC. FDR = first-degree relative; IQR = interquartile range (ie, 25th--75th percentile); NOS = not otherwise specified; OC = epithelial ovarian cancer.

Fifty-one OC patients (16.7%, 95% confidence interval \[CI\] = 12.8% to 21.5%) had a tumor *BRCA1/2* pathogenic variant, 27 (52.9%) in *BRCA1* and 24 (47.1%) in *BRCA2*. Of 44 patients who completed genetic predisposition testing, 25 (56.8%, 95% CI = 41.1% to 71.3%) had hereditary pathogenic variants ([Table 2](#djz080-T2){ref-type="table"}), and 19 (43.2%, 95% CI = 28.7% to 58.9%) had somatic pathogenic variants ([Table 3](#djz080-T3){ref-type="table"}). *BRCA1* hypermethylation was found in 34 of 305 cases (11.1%, 95% CI = 7.9% to 15.4%). Pathogenic variants and *BRCA1* hypermethylation were mutually exclusive ([Figure 1](#djz080-F1){ref-type="fig"}). Only two OC patients had *BRCA* variants of unknown significance in the absence of a pathogenic *BRCA1* or *BRCA2* variant ([Supplementary Table 1](#sup1){ref-type="supplementary-material"}, available online).

###### 

Characteristics of 25 epithelial ovarian cancer patients with a pathogenic *BRCA1/2* hereditary variant identified with the universal tumor *BRCA1/2* workflow

  Gene      Mutation c.[\*](#tblfn2){ref-type="table-fn"}    Mutation p.[\*](#tblfn2){ref-type="table-fn"}  Mutation position   Age OC, y   OC histology       FIGO stage   NCCN guideline   Personal history of breast cancer   FDR/SDR family history                                     
  --------- ----------------------------------------------- ----------------------------------------------- ------------------- ----------- ------------------ ------------ ---------------- ----------------------------------- ---------------------------------------------------------- ----------------
  *BRCA1*   c.68_69del                                                        p.(Glu23fs)                   Neither             50          HGS                IIIc         Familial         --                                  FDR 48                                                     SDR 56
  *BRCA1*   c.633C\>T                                        p.(Gln172[\*](#tblfn2){ref-type="table-fn"})   Neither             56          HGS                IIIc         Personal         47 ER- PR- Her2-                    FDR 35 + 36, FDR 44, FDR 41 + 54, SDR 35, SDR 38, SDR 48   SDR 61
  *BRCA1*   c.981_982del                                     p.(Cys328[\*](#tblfn2){ref-type="table-fn"})   Neither             55          Undifferentiated   n/a          Personal         53 TN                               --                                                         --
  *BRCA1*   c.2197_2201del                                                   p.(Glu733fs)                   OCCR                57          HGS                n/a          Familial         --                                  FDR 54                                                     FDR 53, FDR 84
  *BRCA1*   c.2197_2201del                                                   p.(Glu733fs)                   OCCR                73          HGS                IIIc         No               --                                  FDR 70                                                     --
  *BRCA1*   c.2338C\>T                                       p.(Gln780[\*](#tblfn2){ref-type="table-fn"})   OCCR                41          HGS                n/a          Familial         --                                  --                                                         SDR 54
  *BRCA1*   c.2685_2686del                                                   p.(Pro897fs)                   OCCR                64          HGS                n/a          Personal         52 ER- PR- Her2?                    SDR \<40, SDR, SDR                                         --
  *BRCA1*   c.2722G\>T                                       p.(Glu908[\*](#tblfn2){ref-type="table-fn"})   OCCR                58          HGS                n/a          Familial         --                                  FDR 41, SDR 65-70, SDR \<43                                --
  *BRCA1*   c.2722G\>T                                       p.(Glu908[\*](#tblfn2){ref-type="table-fn"})   OCCR                67          HGS                n/a          Personal         53 TN                               FDR 55                                                     --
  *BRCA1*   c.5095C\>T                                                      p.(Arg1699Trp)                  Neither             65          HGS                n/a          Familial         --                                  FDR 36, SDR 75                                             --
  *BRCA1*   c.5216A\>T                                                      p.(Asp1739Val)                  Neither             58          HGS                n/a          No               --                                  FDR 57, SDR                                                --
  *BRCA1*   c.5291T\>C                                                      p.(Leu1764Pro)                  BCCR                42          HGS                IV           No               --                                  --                                                         --
  *BRCA1*   c.5309C\>T                                                      p.(Gly1770Val)                  BCCR                35          HGS                Ic           No               --                                  --                                                         --
  BRCA2     c.1147del                                                        p.(Ile383fs)                   BCCR                49          Clear cell         Ia           No               --                                  --                                                         --
  *BRCA2*   c.3814del                                                        p.(Met1272fs)                  OCCR                57          HGS                n/a          No               55 ER+ HR+ Her2?                    --                                                         --
  *BRCA2*   c.4314del                                                        p.(Ala1439fs)                  OCCR                61          Undifferentiated   II           No               --                                  --                                                         --
  *BRCA2*   c.4449del                                                        p.(Asp1484fs)                  OCCR                65          Carcinosarcoma     n/a          No               --                                  --                                                         --
  *BRCA2*   c.5213_5216del                                                   p.(Thr1738fs)                  OCCR                51          HGS                n/a          No               --                                  SDR 50                                                     --
  *BRCA2*   c.5213_5216del                                                   p.(Thr1738fs)                  OCCR                55          HGS                n/a          No               --                                  --                                                         --
  *BRCA2*   c.5213_5216del                                                   p.(Thr1738fs)                  OCCR                57          HGS                IIIc         No               --                                  --                                                         --
  *BRCA2*   c.5213_5216del                                                   p.(Thr1738fs)                  OCCR                70          HGS                n/a          Familial         --                                  FDR 44/52                                                  FDR 79
  *BRCA2*   c.5645C\>A                                       p.(Ser1882[\*](#tblfn2){ref-type="table-fn"})  OCCR                52          HGS                n/a          Familial         --                                  FDR 36                                                     --
  *BRCA2*   c.6275_6276del                                                   p.(Leu2092fs)                  Neither             64          HGS                n/a          Familial         64                                  FDR 45                                                     --
  *BRCA2*   c.7617 + 1G\>T                                                        p.?                       Neither             73          HGS                n/a          Personal         68                                  FDR 35, FDR 57, FDR 65, SDR 40                             --
  *BRCA2*   c.9672dup                                                        p.(Tyr322fs)                   Neither             79          HGS                IIIc         No               62                                  --                                                         --

Variant nomenclature according to Human Genome Variation Society guidelines (varnomen.hgvs.org). FDR = first-degree relative; FIGO = International Federation of Gynecology and Obstetrics; HGS = high-grade serous; n/a = not available; NCCN = National Comprehensive Cancer Network; OC = epithelial ovarian cancer; SDR = second-degree relative; -- = a negative history.

###### 

Characteristics of 19 epithelial ovarian cancer patients with a pathogenic somatic *BRCA1/2* variant identified with the universal tumor *BRCA1/2* workflow

  Gene      Mutation c.[\*](#tblfn3){ref-type="table-fn"}                                             Mutation p.[\*](#tblfn3){ref-type="table-fn"}   Age OC, y   OC histology            FIGO stage   NCCN guideline    Personal history of breast cancer  FDR or SDR family history   
  --------- ----------------------------------------------------------------------------------------- ----------------------------------------------- ----------- ----------------------- ------------ ---------------- ----------------------------------- --------------------------- --------
  *BRCA1*   c.3013del                                                                                 p.(Glu1005[\*](#tblfn3){ref-type="table-fn"})   84          HGS                     n/a          No                               --                  --                             --
  *BRCA1*   c.3031del                                                                                 p.(Glu1011fs)                                   55          HGS                     n/a          No                               --                  --                             --
  *BRCA1*   c.3037del                                                                                 p.(Glu1013fs)                                   77          HGS                     n/a          No                               --                  --                             --
  *BRCA1*   c.3205C\>T                                                                                p.(Gln1069[\*](#tblfn3){ref-type="table-fn"})   52          Endometrioid            n/a          No                               --                  --                             --
  *BRCA1*   c.3710dup                                                                                 p.(Pro1238fs)                                   59          HGS                     IIIc         Personal                  52 ER? HR? Her2?           SDR 68                         --
  *BRCA1*   c.4814T\>A                                                                                p.(Leu1605[\*](#tblfn3){ref-type="table-fn"})   77          Undifferentiated        n/a          Personal                  54 ER? HR? Her2?           SDR 60                         --
  *BRCA1*   c.5363G\>T                                                                                p.(Gly1788Val)                                  68          HGS                     n/a          Familial                         --                  FDR 64 SDR 64                  --
  *BRCA1*   Duplication exons 1--20                                                                   p.?                                             41          Mucineus                n/a          No                               --                  --                             --
  *BRCA1*   Deletion of exons 1--11,or duplication of exons 11--24[†](#tblfn4){ref-type="table-fn"}   p.?                                             53          HGS                     n/a          No                               --                  --                             --
  *BRCA2*   c.3826G\>T                                                                                p.(Glu1276[\*](#tblfn3){ref-type="table-fn"})   46          Endometrioid            n/a          No                        46 ER+ HR+ Her2--          --                             --
  *BRCA2*   c.4085del                                                                                 p.(His1362fs)                                   54          HGS                     n/a          No                               --                  --                             --
  *BRCA2*   c.4908del                                                                                 p.(Val1637fs)                                   76          HGS                     Ic           No                               --                  FDR 61                         --
  *BRCA2*   c.5048dup                                                                                 p.(Thr1684fs)                                   68          HGS                     IIIc         Personal                  65 ER+ PR+ Her2--          SDR 50 Male SDR age?           --
  *BRCA2*   c.5465del                                                                                 p.(Asn1822fs)                                   57          HGS                     IIIc         Familial                         --                  --                           FDR 74
  *BRCA2*   c.5942_5961del                                                                            p.(Ala1981fs)                                   79          HGS                     IIIc         No                               --                  --                             --
  *BRCA2*   c.7530_7531del                                                                            p.(Tyr2511fs)                                   66          Serous, grade unknown   n/a          No                               --                  SDR age?                       --
  *BRCA2*   c.7792G\>T                                                                                p.(Glu2598[\*](#tblfn3){ref-type="table-fn"})   66          HGS                     n/a          No                               --                  FDR 70                         --
  *BRCA2*   c.799G\>T                                                                                 p.(Gly267[\*](#tblfn3){ref-type="table-fn"})    49          Endometrioid            IIIa         No                               --                  --                             --
  *BRCA2*   c.9360del                                                                                 p.(Ile3120fs)                                   56          Serous, low grade       Ic           No                               --                  --                             --

Variant nomenclature according to Human Genome Variation Society guidelines (varnomen.hgvs.org). FDR = first-degree relative; FIGO = International Federation of Gynecology and Obstetrics; HGS = high-grade serous; MLPA = multiplex ligation-dependent probe amplification; n/a = not available; NCCN = National Comprehensive Cancer Network; OC = epithelial ovarian cancer; SDR = second-degree relative; -- = a negative history.

With MLPA, it is not possible to make a distinction between a 5' deletion or 3' duplication.

Patients with pathogenic hereditary *BRCA1/2* variants were younger at OC diagnosis than patients without any tumor *BRCA1/2* pathogenic variants (median 57 years, IQR = 52--65 years vs median 66 years, IQR = 57--73 years, respectively, *P *=* *.009) ([Table 4](#djz080-T4){ref-type="table"}; [Supplementary Figure 2](#sup1){ref-type="supplementary-material"}, available online). Patients with pathogenic hereditary *BRCA1/2* variants were more likely to have high-grade serous OC than patients without tumor variants (84.0% vs 61.0%, *P *=* *.09), with no statistically significant difference between patients with a *BRCA1* or *BRCA2* variant (92.3% vs 75.0%, *P *=* *.26; [Table 2](#djz080-T2){ref-type="table"}). Based on their personal and family history of cancer, 13 (52.0%) patients with pathogenic hereditary *BRCA1/2* variants (69.2% *BRCA1* and 33.3% *BRCA2*, *P *=* *.12) already complied with National Comprehensive Cancer Network (NCCN) criteria for *BRCA1/2* testing before their OC diagnosis ([Table 2](#djz080-T2){ref-type="table"}), suggesting their tumors could have been prevented by earlier genetic testing in relatives and presymptomatic cascade testing.

###### 

Characteristics of epithelial ovarian cancer patient by *BRCA1/2* tumor and germline (hereditary) status

  Workflow characteristics               No *BRCA1/2* mutation n = 254   Germline mutation n = 25   Somatic mutation [\*](#tblfn5){ref-type="table-fn"}n = 19   *P* [†](#tblfn6){ref-type="table-fn"}          
  -------------------------------------- ------------------------------- -------------------------- ----------------------------------------------------------- --------------------------------------- ------ -----
  Age at OC diagnosis, median (IQR), y   66 (57--73)                     57 (52--65)                59 (54--72)                                                 1.0                                     .009   .90
  Initial OC histology, No. (%)                                                                                                                                 .27                                     1.0    1.0
   Serous, low grade                     16 (6.3)                        --                         1 (5.3)                                                                                                    
   Serous, high grade                    155 (61.0)                      21 (84.0)                  12 (63.2)                                                                                                  
   Serous, unknown grade                 17 (6.7)                        --                         1 (5.3)                                                                                                    
   Mucinous                              16 (6.3)                        --                         1 (5.3)                                                                                                    
   Endometrioid                          12 (4.7)                        --                         3 (15.8)                                                                                                   
   Clear cell                            18 (7.1)                        1 (4.0)                    --                                                                                                         
   Carcinosarcoma                        9 (3.5)                         1 (4.0)                    --                                                                                                         
   Adenocarcinoma NOS                    2 (.8)                          --                         --                                                                                                         
   Undifferentiated                      6 (2.4)                         2 (8.0)                    1 (5.3)                                                                                                    
  HGS OC, No. (%)                                                                                                                                                                                              
   Yes                                   155 (61.0)                      21 (84.0)                  12 (63.2)                                                   .49                                     .09    1.0
   No                                    99 (39.0)                       4 (16.0)                   7 (36.8)                                                                                                   

This includes only patients for whom the presence of a *BRCA1/2* germline mutation was evaluated; hence, seven patients for whom results of germline diagnostics are unavailable were excluded. HGS = high-grade serous; IQR = interquartile range; NOS = not otherwise specified; OC = epithelial ovarian cancer; -- = a count of zero.

*P* values were calculated with Mann-Whitney *U* tests or Fisher exact tests and adjusted with a Bonferroni correction for the three group comparisons.

Two tumors with a somatic pathogenic *BRCA1/2* variant additionally harbored multiple other somatic variants in *BRCA1* and/or *BRCA2*. In both tumors, a somatic pathogenic *POLE* variant was detected as the driver genetic defect.

Referral for Genetic Counseling and *BRCA1/2* Genetic Predisposition Testing
----------------------------------------------------------------------------

Of 51 patients with a tumor *BRCA1/2* pathogenic variant, 45 (88.2%) were referred for genetic counseling, of whom 44 chose genetic predisposition testing and 1 patient postponed her genetic counseling to a later time ([Table 1](#djz080-T1){ref-type="table"}). In total, six patients were not referred, of whom four died shortly after diagnosis. Two patients with a pathogenic *BRCA1/2* variant in their OC were erroneously not referred. Of 254 patients without tumor *BRCA1/2* pathogenic variants, 34 (13%) were referred for genetic counseling and genetic predisposition testing, including two referrals indicated by a first-degree relative with OC.

Of 315 patients with a tumor DNA *BRCA1/2* test, 275 (87.3%) were either appropriately referred (55 of 63) or not referred (220 of 252) ([Table 1](#djz080-T1){ref-type="table"}). The appropriate referral rates remained stable over time, and the number of unjustified referrals---no tumor mutation and no suspected family history---decreased as fewer patients were referred before their negative tumor test result was available ([Figure 2](#djz080-F2){ref-type="fig"}).

Patient Experiences
-------------------

Of 18 invited patients, 13 (72.2%) consented to the telephone interview. This included four (30.8%) patients with hereditary, three (23.1%) with somatic, and six (46.2%) without *BRCA1/2* pathogenic variants. Two patients (one with a somatic variant and one without a tumor *BRCA1/2* pathogenic variant) were unaware of their tumor test. However, all appreciated that the tumor test was done, and they were satisfied with the amount and nature of the information provided by their physician. The patients specifically valued the speed with which the procedure allowed them to obtain relevant knowledge on heredity. Patients' suggestions for improvement focused on reduction of waiting time after referral for genetic counseling to evaluate heredity of the identified tumor *BRCA1/2* variant immediately.

Gynecologist Experiences
------------------------

Questionnaire responses were received from 18 of 41 (43.9%) invited gynecologists. Fifteen (83.3%) were mostly or completely positive about universal tumor DNA *BRCA1/2* testing, and one (5.6%) was mostly negative. Gynecologists indicated that the workflow could be further improved by quicker tumor test results (5 of 18), better communication of the tumor test results to the gynecologist (11 of 18), and more available information for patients (10 of 18). Sixteen gynecologists (88.9%) agreed with the statement that the gynecologist is the most suited physician to discuss tumor DNA *BRCA1/2* testing, but one (5.6%) was of the opinion that tumor DNA *BRCA1/2* testing should be performed only after formal clinical genetic counseling. The majority (14 of 18, 77.8%) of the gynecologists considered the test turnaround time to be adequate, but several gynecologists stated that they had to schedule an additional appointment to discuss the outcome. Explaining tumor DNA *BRCA1/2* testing and reporting negative results took less than 5 minutes for all responding gynecologists, and one-half (9 of 18) needed more than 5 minutes to explain the relevance of a detected variant. The gynecologists perceived that the understanding of patients was considered good before testing in 55.6%. After disclosure and discussion of test results, this increased to 86.1%.

Discussion
==========

Universal tumor DNA *BRCA1/2* testing in OC patients was shown to be feasible in daily practice, and patients and gynecologists were overwhelmingly positive about this workflow. Universal tumor testing was performed in 77.6% of the patients and yielded 16.7% pathogenic *BRCA1/2* variants in the tumor DNA, whereas a pathogenic variant would have been detected in only 9.5% of patients with universal genetic predisposition testing. Hence, the universal tumor *BRCA1/2* workflow identified twice as many patients for PARPi therapy than conventional genetic predisposition testing of DNA from blood could have detected.

PARPi therapies are becoming more and more important to improve the generally poor prognosis of OC ([@djz080-B14],[@djz080-B18]). Under current universal OC genetic predisposition testing guidelines, up to 90.5% of patients would receive two genetic tests because they are negative for a hereditary variant and would need a subsequent tumor test to identify somatic *BRCA1/2* variants. The universal tumor testing workflow is more effective and reduces the number of tests by 38.7% because in about 16.7% of the patients, subsequent heredity genetic counseling and a blood test are needed. Furthermore, tumor *BRCA1/2* status is available shortly after OC diagnosis, which is advantageous now that maintenance treatment with PARPi after first-line chemotherapy has been shown to be effective ([@djz080-B14]).

By focusing on treatment options, the strategy may improve uptake of *BRCA1/2* testing in patients with OC. In our study, we showed that after an implementation learning period of 6 months, 70.4% of the OC followed the intended workflow: 81.6% of newly diagnosed OC patients received universal tumor DNA *BRCA1/2* testing, and 86.3% of those who tested positive received genetic counseling and testing. The performance of the workflow can likely be generalized to each hospital setting because no difference existed between university and community hospitals. The high uptake may also be reached by conventional genetic predisposition testing because active implementation of universal testing yielded uptake rates up to 74%--90% ([@djz080-B19]), which is far beyond reported uptake of universal *BRCA1/2* genetic predisposition testing in OC in the United States and Canada of only 10%--30% ([@djz080-B22],[@djz080-B23]). However, the waiting lists for genetic counseling and genetic predisposition testing may stagnate the increasing uptake ([@djz080-B24]). Testing tumor DNA will effectively serve as a prescreen to tailor genetic counseling to those with a high a priori risk of a hereditary pathogenic variant. From our data, we conclude that it will diminish by sixfold the number of patients needing genetic counseling and genetic predisposition testing.

In this study, tumor *BRCA1/2* pathogenic variants were identified in 16.7% of OCs. This rate is in line with previously reported rates of 18%--24% ([@djz080-B6]). The proportion of pathogenic hereditary *BRCA1/2* variants of 56.8% is similar to rates found in another recent cohort (54%) but low compared with 62%--74% in other studies ([@djz080-B5]). Possible explanations can be low prevalence of founder mutations and reduction of *BRCA1/2*-associated tumors due to relatively high uptake of predictive genetic testing and subsequent preventive measures in our population ([@djz080-B25]).

It is essential that the test on FFPE tumor material as a prescreen for genetic counseling and genetic predisposition testing is equally reliable as genetic predisposition testing on DNA derived from peripheral blood lymphocytes. Our validated approach with smMIP-based NGS and MLPA detects all known pathogenic hereditary *BRCA1/2* variants ([@djz080-B15]). During our study, the CNV analysis by MLPA was impossible for 3.1% OCs with successful smMIP-based NGS, which leads to a minor decrease in sensitivity of the tumor test. However, exon deletions and duplications form a minority of the pathogenic hereditary variants, and only two somatic exon deletions or duplications were present in the 297 samples that could be evaluated for these types of variants. Overall, we conclude that it is safe and feasible to replace *BRCA1/2* genetic predisposition testing by *BRCA1/2* tumor DNA testing as a prescreen for *BRCA1/2* genetic predisposition testing when performed in an accredited genetic diagnostic laboratory after rigorous validation of the assay.

A strength of this study is that the novel workflow was implemented in the daily clinical practice of multiple centers through which realistic uptake rates could be assessed. However, this limited the possibility to assess why patients did not undergo a tumor test or predisposition testing. The uptake of cancer predisposition testing may therefore be even higher because some patients may have received testing at other genetic centers.

In conclusion, universal *BRCA1/2* tumor testing in all new OC patients simultaneously facilitates treatment and genetic screening purposes and is very well appreciated by participating patients and gynecologists. It is more effective than current guideline advice with universal genetic predisposition testing because it reduces the number of tests and consultations needed and provides information on tumor *BRCA1/2* variants shortly after diagnosis, enabling personalized treatment choices with PARPi. It also reaches patients with somatic variants and patients who are underrepresented in clinical genetic counseling and genetic predisposition testing, such as patients with a low educational level and non-Caucasian background ([@djz080-B26]). Universal tumor DNA *BRCA1/2* testing is a robust and suitable option that effectively and efficiently increases the opportunity for targeted treatment in patients and cancer prevention in relatives.
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